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esponsibility of InstAbstract Acting as immune cells, microglia play a surveillance role in central nervous system injuries
and diseases. Extracellular nucleotides such as ATP and UTP, and adenosine are reported to regulate the
response of microglia to insults and disease. ATP activates P2X receptors and triggers several signal
cascades, resulting in the activation of microglia. Subsequently, UDP binding to the P2Y6 receptor
induces phagocytosis by microglia, while adenosine regulates process retraction in microglia. Nucleotides
and adenosine leak out from dead cells and act on their corresponding receptors on microglia, stimulating
the release of inﬂammatory factors and cytokines to provide both neurotrophic and neurotoxic effects.
In this article, we review the regulatory effects of nucleotides and adenosine on microglial chemotaxis,
phagocytosis, and process retraction, and summarize the activities of these cells after ischemia.
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Z. Li et al.2061. Introduction
Microglia, which function in phagocytosis, secretion and in
nutritional support, are considered as sensors of pathological
changes in the central nervous system (CNS). Ischemia, trauma
and other brain injuries cause microglia to undergo a conforma-
tional change with the formation of plasma membrane extensions
(“processes”) and enhanced motility. In physiological conditions,
microglia in the brain maintain a “resting” state, characterized by a
speciﬁc ramiﬁed morphological phenotype. Subsequent to
“damage” signals, resting microglia ﬁrstly stretch processes to
surround dead cells. Then, with the depletion of chemotaxin,
microglia retract these processes and adopt an “ameboid” mor-
phology so as to phagocytose dead cells and debris, or to release
neurotrophic and cytotoxic cytokines1,2.
Previous studies have shown that the activation of microglia
involves many signaling pathways, cytokines and growth factors.
In recent years, endogenous nucleotides and adenosine have been
shown to be key messengers in microglial activation process3,4.
Nucleotides act on neurons and glia cells as neural transmitters.
Massive accumulations of extracellular nucleotides released from
astrocytes5 and dead cells after damages occur6 activate receptors
on microglia and initiate a series of intracellular signaling cascades
which mediate the activation of microglia. Furthermore, extra-
cellular ecto-nucleotidases quickly degrade ATP to ADP, AMP
and adenosine which also act on microglial cells, combining with
other ATP derivatives released from damaged cells. In this article,
we describe how nucleotides and adenosine activate microglia and
the role of microglia after cerebral ischemia.2. Nucleotides and adenosine signals
Purines (ATP, ADP and adenosine) and pyrimidines (UTP and
UDP) are signals that regulate microglial movement and function
in the CNS. ATP, ADP, and UTP have been reported to activate
chemotaxis and movement of microglia3,7,8. UDP regulates
microglial phagocytosis4,9, and adenosine is associated with
microglial process retraction10.
Nucleotides and adenosine can be released into the extracellular
milieu from aggregating platelets, degranulating macrophages,
excitatory neurons, and injured cells11. Adenosine and ATP are
released by synaptic transmission to maintain cell-to-cell commu-
nication. Under pathological conditions, extracellular adenosine
and nucleotides are released in response to brain injuries, such as
ischemia, oxidative stress, hypoxia and mechanical stretch. ATP
released from vesicles of damaged neurons stimulates the release
of more ATP from surrounding glial cells12. Extracellular ADP
comes directly from injured tissues or break-down of ATP, while
adenosine is mainly derived from the degradation of ATP13.
Injured cells also release pyrimidine nucleotides including UTP,
which is rapidly degraded to UDP, UMP and uridine. These
signals induce microglial migration and chemotaxis by binding to
the corresponding nucleotide receptors.3. Nucleotides and adenosine receptors on microglia
The effects of purines and pyrimidines are implemented by acting on
P1 and P2 receptors, which have a widespread presence in the brain.
P1 receptors are primarily activated by adenosine, but some may also
be activated by inosine, an immediate metabolite of adenosine. P1receptors have been shown to be associated with the regulation of sleep
and arousal, locomotion, anxiety, cognition and memory14. There are
four subtypes of P1 receptors, A1, A2A, A2B and A3 receptors, all of
which are seven-membrane-spanning and G-protein-coupled receptors.
The four types of P1 receptors are expressed or co-expressed on
microglia, astrocytes and neurons. A1, A2A, A2B and A3 receptors on
microglia reveal different functions and their activation depends on the
concentration of adenosine and the phenotypes of the cells15,16.
Microglia from healthy adult brains express high levels of A1 and
A3 receptors17. Under physiological conditions, A2A receptor expres-
sion in microglia is usually undetectable. However, when induced by
brain insult, microglia A2A receptor expression is increased with the
accompanying release of adenosine and pre-inﬂammatory cytokines16.
Activation of P1 receptors regulates microglia proliferation, process
extension, the expression of cyclooxygenase 2 (COX-2)18 and the
subsequent secretion of prostaglandin E2 (PGE2), the production of
nerve growth factor (NGF)19 and the phosphorylation of ERK1/220.
P2 receptors are categorized as ionotropic P2X receptors and
metabotropic P2Y receptors. P2X receptors are ligand-gated ion
channel receptors, which presently comprise seven subtypes from
P2X1 to P2X7, all of which are primarily activated by ATP. All P2X
receptor channels are permeable to Na+, K+ and Ca2+, while some of
them are permeable to Cl−. P2Y receptors, like P1 recep-
tors, are seven-membrane-spanning, G-protein-coupled receptors com-
prised of eight subtypes which are activated by the purines ATP and
ADP, and the pyrimidines UTP, UDP and UDP glucose21. These
subtypes are designated as P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12,
P2Y13 and P2Y1421,22. A new P2Y-like receptor, G protein-coupled
receptor 17 (GPR17), recently was found to respond to both uracil
nucleotides and cysteinyl leukotrienes23.
Microglia express both P2X and P2Y receptors, including
P2X4, P2X7, P2Y2, P2Y4, P2Y6, P2Y12, P2Y14 and GPR17
receptors4,24–27. ATP activates the P2X7 receptor on microglia to
promote microglia proliferation and trigger microglia to release
inﬂammatory mediators to induce inﬂammation25. The P2Y2
receptor and the P2Y4 receptor are associated with the movement
of microglia induced by ATP, ADP and UTP. The P2X4 receptor
and the P2Y12 receptor are involved in microglial migration and
process extension induced by ATP and ADP13. UDP activates the
P2Y6 receptor to regulate microglial phagocytosis27.4. Nucleotide signals regulate microglia motility
4.1. Microglia chemotaxis
Microglia chemotaxis includes process extension and cell body
migration in response to an extracellular signaling factor. It is a
coordinated process involving a cell membrane extension at the
front edge and displacement of the cell body.
Numerous factors stimulate microglial chemotaxis, including pur-
inergic agonists26, complement proteins27,28, epidermal growth factor29,
cannabinoids30, macrophage inﬂammatory protein-1 (MIP-1)31,32,
macrophage chemoattractant protein-1 (MCP-1)33, neurotrophic factors,
such as NGF and EGF32,34, amyloid-beta35,36, neuropeptide bradyki-
nin37, neuregulin-138, and various other chemokines32,39,40. ATP and
its metabolite adenosine appear to function as chemoattractants or
“ﬁnd-me” signals from damaged neurons to microglia. When acute
brain injuries occur, microglia are transformed into a process-extending
phenotype, dramatically increasing their motility. Microglia immedi-
ately extrude processes to the injured site, by which they prevent the
spread of the lesion in the brain41.
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P2Y12 receptor-deﬁcient mice, indicating that rapid process
extension is dependent on ATP through microglial P2Y12
receptors42. Later it was demonstrated that simultaneous stimula-
tion of both P2Y12 receptor and A3 receptor is required for
process extension43. The P2Y12 receptor-mediated microglial
migration is facilitated or modulated strongly by other P2 or P1
receptor-mediated signals, such as P2X4 receptor activation, which
is normally expressed at a low level and is upregulated in activated
microglia within 24 h after injury44–47. When the P2X4 receptor is
activated by ATP, extracellular Ca2+ inﬂux is increased and the
phosphoinositide 3-kinase (PI3K) pathway is activated to regulate
microglia chemotaxis and remodel the cellular morphology.
Further studies suggested that P2Y12-associated potassium
channels are required for ATP-induced chemotaxis and the base-
line motility of microglia45. Once chemoattractant binds to cell
surface receptors, cytoskeletal machineries (such as F-actin and
microtubulin) are activated, resulting in an increase in microglia
motility46. Nitric oxide (NO) and glutamate also participate in
control of the chemotaxis direction47,48. With depletion of ATP,
microglia chemotaxis becomes non-directional7.
4.2. Microglia phagocytosis
After migrating to a damaged site, microglia perform endocytic
activities such as pinocytosis, macropinocytosis and phagocytosis,
of which phagocytosis is important in brain protection49. The
phagocytosis process is suggested to be guided by cell-surface
phagocytosis receptors and ligands which activate these receptors,
including Fc receptors, complement receptors, integrins, endotoxin
receptors (CD18, CD14), mannose receptors, scavenger recep-
tors50, and phosphatidylserine (PS) receptors, such as BAI-151 and
Tim452. Activated microglia recognize these signals by
phagocytosis-promoting receptors which include opsonin-
dependent receptors (complement and vitronectin receptors) and
opsonin-independent ones (β1-integrins, mannose receptors, sca-
venger receptors and phosphatidylserine receptors). Then the
activated microglia carry out phagocytosis by uptake into
vacuoles9.
UDP and its P2Y6 receptor are clearly proven to be one of the
signals mediating the phagocytsis process4,53. Resting microglia in
the normal adult brain show almost no expression of P2Y6
receptors. When activated, microglia become phagocytes by
dramatically increasing P2Y6 receptor expression4. After being
attracted to the impaired regions, microglial UDP from injured
cells activates the P2Y6 receptor on microglia and promotes
microglial phagocytosis of dead cells, debris and pathogens4,54.
The process of microglial phagocytosis can be divided into
deformation, recognition, and phagocytosis. Activated by UDP,
P2Y6 receptors are coupled to the activation of phospholipase C,
leading to the production of inositol 1,4,5-trisphosphate (InsP3)
and the release of Ca2+ from InsP3-receptor-sensitive stores. Ca2+
and protein kinase C (PKC) trigger microglia to form ﬁlopodia-
like protrusions and phagosome-like vacuoles for further
phagocytosis9.
4.3. Microglia processes retraction
Ameboid microglia with retractile processes often are present
during chronic brain injury and neurodegenerative diseases55.
Inﬂammatory activation is an essential condition of microgliaprocess retraction, and the retraction, related to actin remodeling,
also serves as a characteristic of brain inﬂammation10. Microglia
repulsion to ATP can be observed after activation by lipopoly-
saccharide (LPS), lipoteichoic acid and tumor necrosis factor α
(TNFα). Blockade of Gas and its downstream adenylate cyclase
(AC) or protein kinase A (PKA) prevents microglial process
retraction, indicating involvement of Gs-coupled signals in the
retraction. During microglial process retraction, A2A receptors
were upregulated and P2Y12 receptors were downregulated10, and
are presumably associated with activated microglia adopting their
characteristic ameboid morphology during brain inﬂammation.4.4. Microglia response is associated with nucleotides and
adenosine receptors activation
The effect of A1 receptor activation on microglia is controversial.
The stimulation of A1 receptors was reported to reduce excessive
activation and proliferation of microglia upon immune activa-
tion46. In a traumatic brain injury mouse model, A1 receptor
knockout enhanced the microglial response and increased the
number of Iba-1 positive microglia by 20–50% in the ipsilateral
cortex, CA3, thalamus, and contralateral cortex56. Loss of A1
receptors also results in an increase in tumor-associated micro-
glia57. These reports are opposite to a previous study that reported
that simultaneous stimulation of both adenosine A1 and A2
receptors increased the proliferation of microglia49. A2A receptor
stimulation would cause activated microglia to assume ameboid
morphology and mediate microglial process retraction during brain
inﬂammation10. The A2A receptor also plays an important role in
mediating the release of inﬂammatory factors by microglia.
Blockade of the A2A receptor by the selective antagonist
SCH58261 prevented the LPS-induced activation of microglia
and decreased the concentration of interleukin-1β in the hippo-
campus, indicating that A2A receptor activation on microglia was
involved in mediating the neuroinﬂammation triggered by LPS58.
In unstimulated microglia, the inhibitory effect of NECA (a
nonspeciﬁc adenosine receptor agonist) on LPS-induced TNFα
production was not inﬂuenced by SCH58261, but in activated
microglia NECA-induced inhibition of both TNFα and IL-12p40/
p70 production was opposed59. However, addition of an A2B
receptor antagonist did not affect the inhibitory effect of NECA,
revealing the important role of A2A receptors but not A2B
receptors in the inhibition of LPS-induced cytokine production.
In a recent study, adenosine has been shown to augment IL-10
production through the A2B receptor by activating murine micro-
glia60. Among the four subtype receptor agonists, only an A3
receptor-selective agonist restored the chemotactic process exten-
sion, and its selective antagonist could inhibit ADP-induced
microglial migration and process extension through activation of
the Jun N-terminal kinase in microglia61. This latter ﬁnding
indicates that the regulation of the A3 receptor on microglia is
involved in process extension, migration and physiological
activity.
Among P2X receptors, P2X4 receptor expression was increased
strikingly only in activated microglia rather than in neurons or
astrocytes, and its activation was an important element to induce
tactile allodynia after nerve injury62. Pharmacological blockade of
P2X4 receptors signiﬁcantly inhibited microglial chemotaxis.
Knockdown of the P2X4 receptor in microglia by RNA inter-
ference through the lentivirus vector system also suppressed
microglial chemotaxis52. The expression and motility of P2X4
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microglial-associated neural diseases. Using single-molecule ima-
ging, Toulme et al.63 found that the P2X4 receptor moved
randomly in resting microglia, and in response to a change in
ATP concentration the receptor was dynamically regulated on
activated microglia and involved the p38 MAPK pathway and
calcium current activation. P2X4 receptor-induced brain-derived
neurotrophic factor (BDNF) release from microglia was also
appeared to evoke increased calcium release and activation of
p38 MAPK64. ATP stimulation could not induce BDNF release
from P2X4 receptor-deﬁcient mouse microglia in primary cul-
tures65. P2X4 receptor is also important in regulating microglia
migration. Horvath et al.66 proved that morphine could enhance
microglial migration and P2X4 receptor expression, and P2X4
receptor antagonism inhibited the migration induced by morphine,
revealing a correlation between microglia migration and P2X4
receptor activation. The promotion of P2X4 receptor trafﬁcking to
the cell surface of microglia involves the release of the lysosomal
enzyme β-hexosaminidase induced by chemokine ligand 2 (CCL2)
and Akt phosphorylation by ATP applied extracellularly67.
P2X7 receptors are widely expressed by immune system cells68.
P2X7 receptor levels were signiﬁcantly increased following the
development of nerve injury, and receptor expression was respon-
sible for the activation of microglia69,70. In rat primary hippo-
campal cultures overexpression of P2X7 receptor is sufﬁcient to
drive the activation and proliferation of microglia without patho-
logical conditions, while oxATP signiﬁcantly attenuated microglia
activation12. In status epilepticus rats, microglial activation was
accelerated by BzATP (a P2X7 receptor agonist), but inhibited by
oxATP in the dentate gyrus, the CA1 hippocampal regions and the
frontoparietal cortex71. Using co-cultures of rat cortical neurons
and microglia, pharmacological approaches proved that P2X7
receptor activation on microglia was necessary for mediating the
injury of neurons72. P2X7 receptor pore conductance rather than
the ion channel is responsible for the induction of microglia
activation and proliferation61. A time-dependent upregulation of
P2X7 receptors was observed on microglia, neurons, and astro-
cytes after cerebral ischemia in rats73. P2X7 receptor also involves
the release of cytokines and inﬂammation factors by microglia.
Inhibition of P2X7 receptor by oxATP obviously decreased the
expression of proinﬂammatory factors and LPS-induced activation
of p38 MAPK and NF-κB74. Stimulation of the P2X7 receptor on
rat microglia by BzATP also increased superoxide production
through PI3K pathway75.
Although there are relatively fewer reports on the P2Y receptor
(relative to P2X), microglial P2Y receptors play an important role
in the phagocytosis and chemotaxis processes of microglial
activation. The P2Y2 receptor can be activated by both ATP and
UTP. The agonists ATP and UTP promoted microglia to increase
the uptake of Aβ, but this did not occur in P2Y2 receptor knockout
cells, indicating that the P2Y2 receptor may be a therapeutic target
in Alzheimer's disease45. In cultured rat microglia, endogenous
nucleotides were able to trigger calcium movement through P2Y2,
P2Y6 and P2Y12 receptors76. Exposed to kainic acid, hippocam-
pal neurons are damaged and leak UTP/UDP in vivo and in vitro,
resulting in neuronal cell death4,9,77. In addition, P2Y6 receptor
expression and activated microglia were found to be increased,
indicating the P2Y6 receptor as the sensor to trigger microglial
phagocytosis in response to UDP signals4,9,62. A speciﬁc antago-
nist of P2Y6 (MRS2578) or small interfering RNA directed
against the P2Y6 mRNA reduced UDP-induced chemokine
expression59. P2Y12 receptor expression is mainly evident in“resting” microglia. When coupled with ADP, the receptor is
down-regulated and it regulates microglial polarization, migration
and process extension in vitro and in vivo78. P2Y12 and P2Y1
guide microglia toward the lesion79 and the chemotaxis effect may
be regulated by Akt phosphorylation in microglia52,80.
The P2X7 receptor may be the ﬁrst receptor which senses ATP
signaling and triggers microglia activation, while the P2X4
receptor is responsible for the release of neurotrophins70. The
P2Y12 receptor controls the direction of microglial chemotaxis
and the P2Y6 receptor regulates microglial phagocytosis.5. Nucleotide signals induce microglia response in cerebral
ischemia
Microglia respond signiﬁcantly to their surroundings and phago-
cytose dying cells and cellular debris after ischemia. Zhang et al.81
have observed time-dependent morphological changes in microglia
through 1–166 h after onset of transient (2 h) middle cerebral
artery occlusion (MCAO) reperfusion. Microglia were absent in
the ischemic lesion in which most neurons were lost after 1 h, but
scattered ameboid microglia were detected in the adjacent area. At
2–10 h after onset of reperfusion, round, ramiﬁed and ameboid
microglia appeared in the core area of the lesion and became
predominant in the core lesion, while highly ramiﬁed microglia
were localized at the boundary of the ischemic lesion after 22 h of
reperfusion. At 46 h, round and ameboid cells were detected in the
boundary region of the ischemic lesion and can be observed in the
whole ischemic area throughout 70–166 h after reperfusion.
In the early stage of injury, microglial chemotaxis provided
protection and reparation effects on injured tissues. The activated
microglia encircle and separate the damaged cells by their
extended processes, phagocytose dead cells or debris, and release
neurotrophic factors. On the other hand, numerous studies reported
that activation of microglia over a prolonged period induces the
release of inﬂammatory factor and exacerbates ischemic injury. A
number of drugs have been used to treat cerebral ischemia injury
by inhibiting microglia activation. Treatment with minocycline
signiﬁcantly decreased microglial activation in the hippocampus
and cortex which attenuated neuron degradation in asphyxia-
induced cardiac arrest rats82. Suppression of microglial activation
attenuated infarct volume in the injured cortex 72 h after MCAO83,
and protected against hippocampal cell loss and cognitive deﬁcits
by reducing inﬂammatory markers84. Therefore, mediating the
motility of microglia and controlling the activation process are
essential for the treatment of cerebral ischemia.
5.1. Extracellular signals change after ischemia
ATP outﬂow showed a tendency to increase over time during the
220 min after ischemia in vivo, and the extracellular ATP level was
signiﬁcantly increased in the presence of the ecto-5′-nucleotidase
inhibitor85. Following ATP release caused by hypoxia and
ischemia, a rapid and remarkable increase in extracellular level
of adenosine in the brain can also be observed. During a 20 min
period of ischemia, the adenosine level increased ﬁve-fold86. In a
global or focal ischemic rat model, adenosine in the striatum,
cortex or hippocampus increased more than eight-fold87. Concur-
rently, the enzyme responsible for hydrolyzing extracellular ATP
was also up-regulated88.
Neurons and astrocytes are mainly responsible for the injury-
induced release of ATP89. Extracellular ATP also caused an increase
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nucleotide pools with 14C-adenine90. This study also showed a
Ca2+-independent response of astrocytes. The most common means
of ATP release from astrocytes is through ATP binding-cassette
proteins, such as cystic ﬁbrosis transmembrane conductance regulator
(CFTR), sulfonylurea receptor (SUR), and others. The P2X7
receptor-mediated ion channel also contributes to ATP release.
Adenosine outﬂow accompanied by neurological deﬁcits was
indicated by microdialysis in MCAO rats91. Adenosine is derived
directly from cells and the degradation of extracellular ATP. Uracil
nucleotides signals receive relatively less attention compared to ATP
and adenosine. However, recent studies have demonstrated that the
UDP receptor GPR17 was up-regulated in injured neurons in the
ischemic core and a few microglia in the ischemic core and boundary
zone, and this may reﬂect a mediative effect of uracil nucleotides on
acute neuronal injury and late microgliosis after focal cerebral
ischemia23,92,93.5.2. Nucleotides and adenosine receptors as therapeutic targets
in cerebral ischemia
It is widely accepted that A1 receptor agonists are protective during
ischemia by reducing Ca2+ inﬂux. The neuroprotective function of
chemokine CX3CL1 depends on the activation of the A1 receptor. In
murine models of permanent MCAO, CX3CL1 did not reveal a
neuroprotective effect in the presence of an A1 receptor antagonist or in
A1-receptor knockout mice94. Both in vivo and in vitro studies have
shown that A1 receptor agonists attenuate ischemia induced neural
excitotoxicity. Injection of CCPA (an A1 receptor agonist) into MCAO
rats markedly improved the animals’ behavior and decreased neuronal
apoptosis95. The A1 receptor antagonist (DPCPX) signiﬁcantly atte-
nuated the neuroprotection effect induced by isoﬂurane preconditioning
and resulted in larger infarct volumes after focal cerebral ischemic
injury in rats96. The increased activity of manganese SOD and NO
generation was induced by limb remote ischemic preconditioning or
CCPA was also largely abolished by DPCPX pretreatment97. A2A
receptor activation exerts complex effects (detrimental or protective)
after brain insults. After 24 h in MCAO rats, over expression of the
A2A receptor was found by using an immunohistochemical double-
labeling technique98. Microglial cells proliferate rapidly and release
large amount of pro-inﬂammatory cytokines and increase activation of
nitric oxide synthase (NOS) and release of NO99. These immune
responses exacerbate brain injuries. A2A antagonism was found to be
protective in a model of permanent focal ischemia100. However, in
several studies, A2A receptor agonists have been found to be protective
in a global ischemia model in gerbils101. Using an A3 receptor agonist,
LJ529, which directly inhibited microglia chemotaxis and reduced
migration of microglia after middle cerebral artery occlusion and
reperfusion, resulted in a reduction in the inﬂammatory response and
was neuroprotective102. In MCAO rats, the selective A3 receptor
agonist chloro-N6-(3-iodo-benzyl)-adenosine-5′-N-methyluronamide
(Cl-IB-MEUA) increased locomotor activity and decreased cerebral
infarction 2 days after surgery, and the A3 receptor's protective effect
was also shown with A3 receptor-knockout mice103. The different
effects of adenosine receptors may result from differences in receptor
structure. A1 and A3 receptors are Gi/o coupled receptors which would
inhibit cellular excitability, while A2 receptors are related to Gs protein
and would initiate cellular release of excitatory cytokines which always
accelerate ischemic injury.
In pMCAO rat models, inhibition of P2 receptors by pyridoxalpho-
sphate-6-azophenyl-2′,4′-disulfonic acid (PPADS) improved therecovery of cortical electrophysiological and motor functions; further-
more, PPADS pretreatment led to an initially decreased infarct volume
and reduced cell death up to 7 days after MCAO, compared to
controls104,105. Suramin, a blocker of P2X receptors, at a concentration
of 100 mg/kg signiﬁcantly decreased infarct volume and improved the
neurologic score after ischemia106. In an hypoxia-ischemic rat model,
P2X4 receptor expression and microglial cell activation increased
signiﬁcantly, while inhibition of microglia attenuated the hypoxia-
ischemia-induced increase in P2X4 receptor expression107. De novo
expression of the P2X7 receptor on microglia was demonstrated in
MCAO rats108. ATP promoted the formation and opening of the P2X7
receptor plasma membrane pore to release harmful factors, such as
interleukin 1β (IL-1β), plasminogen, and TNFα, which may produce an
inﬂammatory reaction to aggravate neuronal damage109. Inhibition of
P2X7 receptors by antagonists, such as Brilliant blue G (BBG), oxATP
and A-438079, revealed a dose-dependent increase in survival rates and
a neural-protective effect by reducing the inﬂammatory response in
MCAO rats110,111. However, other researchers did not ﬁnd signiﬁcant
improvement in infarct size after ischemia in mice deﬁcient in the
P2X7 receptor112 and oxATP exacerbated ischemic brain damage113.
These studies reveal a complicated role of P2X7 receptor during
ischemia.6. Conclusions
Nucleotides and adenosine released from injured cells after brain
injury are important signaling molecules that regulate microglial
morphology, chemotaxis, phagocytosis, and process retraction
through related receptors on microglia. Activation of P2X and
P2Y receptors by nucleotides and stimulation of A1, A2A, A2B,
A3 receptors with adenosine derived from ATP degradation
triggers or suppresses the activity of microglia.
The activation of microglia always takes a bidirectional effect
after cerebral injuries. On the one hand, activated microglia
phagocytose dead cells and debris, and secrete neurotrophic factor
to repair injured tissue. On the other hand, uncontrolled activation
of microglia releases inﬂammatory cytokines and results in
phagocytosis of normal cells, aggravating damage. Inﬂammatory
responses play a detrimental role after ischemia. The demarcation
of the both effects is still unclear. Therefore, understanding how
nucleotides and adenosine mediate the release of cytokines and
inﬂammatory factors, and the differentiation of the protective
inﬂuence of microglial activation from harmful effects will provide
better treatment paradigms for cerebral ischemia in the future.
Regulation of microglial activation is mediated by a variety of
complex stimulatory actions at the cellular, molecular and tran-
scriptional levels. At present, most studies focus on using agonists
and antagonists of nucleotides and adenosine receptors to inves-
tigate the role of activated microglia after ischemia in animals. The
roles of most receptors are becoming more clear, but how different
receptors coordinate on the same microglia and how the activation
sequence proceeds during ischemia need further investigation.Acknowledgment
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